SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

Advanced Environmental Petroleum (AEPP)

AEPP RSS Feed
Add AEPP Price Alert      Hide Sticky   Hide Intro
Moderator: reaper247, B0tt0M WaTcH3R, Eltp, fuzzymcilwoods, FIN85, ninersax
Search This Board: 
Last Post: 4/25/2017 1:37:07 AM - Followers: 120 - Board type: Free - Posts Today: 3

 

BIOTECH Merger in Action


April 24 Interview with CEO Michael Redman


On April 6, 2017, in connection with the change of control of the Company, Mr. Kistler resigned as the Company’s sole director, executive officer and other positions and Mr. Redman was appointed a director and our chief executive officer and president and J. Donald Payne as a director and our Secretary and chief accounting officer of the Company.



Verified Company Profile  4/10/2017
Email: mredman@oncolixbio.com
 

AEPP (Advanced Environmental Petroleum Producers) Oncolix, Inc. has become the controlling shareholder

https://www.sec.gov/Archives/edgar/data/1574061/000147793217001787/aepp_sc13d.htm
https://www.sec.gov/Archives/edgar/data/1584137/000147793217001656/aepp_8k.htm



AEPP enters into a SPA (Share Purchase Agreement) with Oncolix, Inc. 


Initial agreement was made on March 7, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74041605

http://ih.advfn.com/p.php?pid=nmona&article=74093500

Merger expected to be finalized on or around April 3, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74157198

AEPP UPDATE:

Change of control of AEPP has been filed with the Florida Secretary of State showing Oncolix CEO

Michael Redman and Oncolix director, Donald Payne as controlling officers of AEPP.

 
AEPP Security Details
Share Structure
  Market Value1 $3,571,704 a/o Apr 07, 2017
Authorized Shares 500,000,000 a/o Mar 30, 2017
Outstanding Shares 93,911,633 a/o Apr 04, 2017
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 33,311,633 a/o Apr 06, 2017
  Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
VStock Transfer LLC
Shareholders
Shareholders of Record 101 a/o Apr 06, 2017

 


Zero outstanding debt

"approximately $111,928 of the $315,000 purchase price will be utilized by the Seller to pay all outstanding indebtedness and financial obligations of the Company so that immediately following the closing of the Share Acquisition (the “ SPAClosing ” ), the Company will have no outstanding indebtedness and/or other financial obligations."
http://ih.advfn.com/p.php?pid=nmona&article=74093500 

April 3, 2017 SPA closing date expected
Due to unanticipated circumstances, the mailing did not occur. As a result, we filed Amendment No. 1 to the Original Filing on March 21, 2017, ( “ Amendment No.1 and together with the Original Filing, collectively, the “ Information Statement ” ), anticipate March 22, 2017 to be the new mailing date and the date of the Board Change and the SPA Closing to occur on or about April 3, 2017 (but in no event earlier than 10 days after the actual mailing date).

Filings from Oncolix after closing will be expected within 4 business days which will detail merger.
Consequently, many more news events will follow with Oncolix releasing details of their business and status of Prolanta as it goes through FDA clinical trials.


 

Who is Oncolix, Inc.?

https://oncolixbio.com

April 2017 Company Presentation:
https://nebula.wsimg.com/8b544fcbb6f5bf5fb52c1c7e5a69eb81?AccessKeyId=D34B304F5C474C27E878&disposition=0&alloworigin=1

POST ACQUISITION INTERVIEW WITH CEO MICHAEL REDMAN

https://www.youtube.com/watch?v=Ox6n1HH8v_0&feature=youtu.be
 

Oncolix, Inc. (Oncolix) is a clinical-stage bio-pharmaceutical company based in Houston, Texas. We are developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer.  This clinical trial is expected to begin in late 2015. Prolanta™ is a prolactin receptor antagonist that has demonstrated significant efficacy in xenograft models through a unique mechanism of action, autophagy (see Our Science). In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers.   

The FDA has also approved the designation of 
Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow an accelerated regulatory approval by the FDA, reduced filing fees, federal tax credits and marketing exclusivity. 

Prolanta is currently in FDA clinical trials phase 1. 
https://clinicaltrials.gov/ct2/show/NCT02534922

Oncolix received Orphan Drug Status for their developmental drug Prolanta.
http://www.bizjournals.com/houston/news/2013/04/24/oncolix-poised-to-start-phase-i-trials.html

8 U.S. Patents have been awarded in the development of Prolanta
http://oncolixbio.com/patents.html

 

PATENTS

The eight US Patents issued to Oncolix are listed in the following table. Non-US patents or applications are not listed.

Patent Number Issue Date Issued To Title
US 7,115,556 03 OCT 2006 Oncolix Use of Anti-Prolactin Agents to Treat Proliferative Conditions
US 7,201,905 10 APR 2007 Oncolix Bi-Functional Cancer Treatment Agents
US 7,339,027

US 8,304,381
4 MAR 2008

6 NOV 2012
Oncolix Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins
US 7,632,809 15 DEC 2009 Oncolix Multimeric Ligands with Enhanced Stability
US 8,648,046

US 8,754,035
11 FEB 2014

17 JUN 2014
Oncolix Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells
US 8,754,031 17 JUN 2014 Oncolix Use of Prolactin Receptor Antagonists in Combination with an Agent that Inactivates the HER2/neu Signaling Pathway

Notable excerpt from company website
Our initial focus is ovarian cancer, and we have an FDA-cleared Investigational New Drug (IND) application to commence a Phase I human trial. Based on our preclinical evidence of expected efficacy, the FDA has also granted Prolanta™ Orphan Drug status for the treatment of ovarian cancer.  Our collaborators at The University Texas MD Anderson Cancer Center developed the efficacy data in ovarian cancer, which was published in Cell Reports (see Scientific Publications). These researchers demonstrated that Prolanta™ has a novel mechanism of action, induced autophagy) against ovarian cancer, and also demonstrated the synergy of Prolanta™ with other chemotherapy drugs. See Ovarian Cancer and Prolanta™.

 

 

The Oncolix Team

Management

\

\

Board Members

\

\

\

Company Advisors

\

\

\


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AEPP
Current Price
Volume:
Bid Ask Day's Range
SureTrader
AEPP News: Initial Statement of Beneficial Ownership (3) 04/24/2017 02:16:03 PM
AEPP News: Statement of Beneficial Ownership (sc 13d) 04/17/2017 04:04:57 PM
AEPP News: Amended Statement of Changes in Beneficial Ownership (4/a) 04/14/2017 10:29:25 AM
AEPP News: Initial Statement of Beneficial Ownership (3) 04/13/2017 12:27:11 PM
AEPP News: Statement of Changes in Beneficial Ownership (4) 04/12/2017 04:03:41 PM
News News Alert: Initial Statement of Beneficial Ownership (3) 04/24/2017 02:16:03 PM
PostSubject
#3823  Sticky Note Interview with CEO Michael Redman fuzzymcilwoods 04/24/17 01:06:53 PM
#3811  Sticky Note VERY IMPRESSIVE "ONCOLIX" APRIL 2017_COMPANY_PRESENTATION: https://nebula.wsimg. Rat Fink 04/23/17 02:31:27 PM
#3776  Sticky Note ninernax, you are absolutely wrong to state a reaper247 04/21/17 12:41:54 AM
#3419  Sticky Note Reverse split is definitely happening. The wording in ninersax 04/11/17 10:53:11 PM
#3887   You still think that filings are trickery? You BLight1911 04/25/17 12:03:35 AM
#3886   and i'm pretty sure it's something oncolix has fuzzymcilwoods 04/24/17 11:58:54 PM
#3885   one of the benefits of going the reverse fuzzymcilwoods 04/24/17 11:57:23 PM
#3884   I don't know but what this CEO is retiredtech 04/24/17 11:47:06 PM
#3883   Unless some company feels that the to-date results retiredtech 04/24/17 11:45:11 PM
#3882   The way I see it MAJOR GAMES are retiredtech 04/24/17 11:42:13 PM
#3881   Requirements for NASDAQ listing fuzzymcilwoods 04/24/17 11:40:54 PM
#3880   just one of the members of the oncolix fuzzymcilwoods 04/24/17 11:35:28 PM
#3879   there has clearly been no merger to this point. fuzzymcilwoods 04/24/17 11:23:33 PM
#3878   Before Oncolix as a company owns the 61 BLight1911 04/24/17 10:48:12 PM
#3877   So this CEO is clearing all officers of retiredtech 04/24/17 10:29:07 PM
#3876   They will and Redman said it publicly via interview B0tt0M WaTcH3R 04/24/17 10:11:19 PM
#3875   I'm just trying to figure out what the dabullishbear 04/24/17 10:09:59 PM
#3874   Most likely.. Looks like they will push media B0tt0M WaTcH3R 04/24/17 10:08:04 PM
#3873   OMG I'm so confused. What the hell is dabullishbear 04/24/17 10:05:34 PM
#3872   I believe NO RS until NASDAQ UPLISTING and B0tt0M WaTcH3R 04/24/17 09:53:25 PM
#3871   Private company will not do RS.. wait for B0tt0M WaTcH3R 04/24/17 09:51:24 PM
#3870   Facts: ninersax 04/24/17 09:49:51 PM
#3869   61M shares owned by Officer of company cannot B0tt0M WaTcH3R 04/24/17 09:39:44 PM
#3867   Open Market???? Show the trade tape that 61M B0tt0M WaTcH3R 04/24/17 09:36:58 PM
#3866  Restored Lol...this gets more and more hilarious by the day. ninersax 04/24/17 09:36:51 PM
#3865   Lol.. Not until there is a merger agreement!!! B0tt0M WaTcH3R 04/24/17 09:35:39 PM
#3864   Really? How long have you been trading? Oncolix ninersax 04/24/17 09:34:17 PM
#3863   From Horses mouth, ONCOLIX still a private company!!! B0tt0M WaTcH3R 04/24/17 09:34:05 PM
#3862   Merger??? Any link it says merger?? B0tt0M WaTcH3R 04/24/17 09:32:58 PM
#3860   Redman continues to say there's been no merger retiredtech 04/24/17 09:27:21 PM
#3858   Really? I saw another filing related to the ninersax 04/24/17 09:20:11 PM
#3857   actually, if they get through phase II with fuzzymcilwoods 04/24/17 09:16:50 PM
#3856   I'd be curious what their buy out price fuzzymcilwoods 04/24/17 09:15:39 PM
#3855   I think it's safe to say this reverse fuzzymcilwoods 04/24/17 09:08:08 PM
#3854   Yes Sir.. I bet there are more media B0tt0M WaTcH3R 04/24/17 09:03:16 PM
#3853   this interview today is the first time i've fuzzymcilwoods 04/24/17 09:01:23 PM
#3852   Buying time for what? Last time I check B0tt0M WaTcH3R 04/24/17 08:15:14 PM
#3851   Never have seen these types of filings before, retiredtech 04/24/17 07:54:36 PM
#3850   Last time you bought a shell did all BLight1911 04/24/17 07:30:56 PM
#3849   How many times can they shuffle that 61M retiredtech 04/24/17 05:48:59 PM
#3846   Nice video! Sungod95 04/24/17 04:42:35 PM
#3845   Someone buying a sh@t ton. Lol Sunbird123 04/24/17 04:27:19 PM
#3844   What's the new filing? Kamstock 04/24/17 04:20:11 PM
#3843   Nice action here!!! B0tt0M WaTcH3R 04/24/17 04:08:38 PM
#3842   This is at least $500M potential company once B0tt0M WaTcH3R 04/24/17 03:07:33 PM
#3841   I'd be happy with .50 but I don't kwisatzhaderach 04/24/17 03:05:23 PM
#3840   I haven't determined an exit point yet.....looking for microcaptrdr24 04/24/17 03:03:21 PM
#3839   Is that your exit point or are you kwisatzhaderach 04/24/17 02:55:01 PM
#3838   True.. Holding here.. this might pop soon B0tt0M WaTcH3R 04/24/17 02:41:05 PM
#3837   between the video and the powerpoint presentation that microcaptrdr24 04/24/17 02:40:31 PM
#3836   Great video Vinnyd321 04/24/17 01:56:33 PM
#3835   That is fast!!!! B0tt0M WaTcH3R 04/24/17 01:51:19 PM
#3834   And losing boatload of $$$$$ in the meantime DayDreeming 04/24/17 01:37:40 PM
#3833   we're waiting to see how the actual reverse fuzzymcilwoods 04/24/17 01:32:06 PM
PostSubject